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Abstract: Burkholderia cenocepacia is an important opportunistic pathogen in cystic fibrosis (CF) 
patients, and has also been isolated from natural environments. In previous work, we explored the 
virulence and pathogenic potential of environmental B. cenocepacia strains and demonstrated that 
they do not differ from clinical strains in some pathogenic traits. Here, we investigated the ability 
of the environmental B. cenocepacia Mex1 strain, isolated from the maize rhizosphere, to persist and 
increase its virulence after serial passages in a mouse model of chronic infection. B. cenocepacia Mex1 
strain, belonging to the recA lineage IIIA, was embedded in agar beads and challenged into the lung 
of C57Bl/6 mice. The mice were sacrificed after 28 days from infection and their lungs were tested 
for bacterial loads. Agar beads containing the pool of B. cenocepacia colonies from the four sequential 
passages were used to infect the mice. The environmental B. cenocepacia strain showed a low 
incidence of chronic infection after the first passage; after the second, third and fourth passages in 
mice, its ability to establish chronic infection increased significantly and progressively up to 100%. 
Colonial morphology analysis and genetic profiling of the Mex1-derived clones recovered after the 
fourth passage from infected mice revealed that they were indistinguishable from the challenged 
strain both at phenotypic and genetic level. By testing the virulence of single clones in the Galleria 
mellonella infection model, we found that two Mex1-derived clones significantly increased their 
pathogenicity compared to the parental Mex1 strain and behaved similarly to the clinical and 
epidemic B. cenocepacia LMG16656T. Our findings suggest that serial passages of the environmental 
B. cenocepacia Mex1 strain in mice resulted in an increased ability to determine chronic lung infection 
and the appearance of clonal variants with increased virulence in non-vertebrate hosts. 
Keywords: Burkholderia cenocepacia; mice; environmental; chronic infection; adaptation; lung tissues; 
Galleria mellonella 
 
1. Introduction 
Cystic fibrosis (CF) is the most common lethal autosomal recessive disease in Caucasians, with 
an incidence of approximately 1 in 2500 live births and a prevalence of approximately 100,000 CF 
patients worldwide [1]. The disease is caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, that encodes a chloride channel localized in both secretory and 
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absorbing epithelia. CFTR dysfunction results in abnormal transport of sodium and chloride ions 
across epithelia affecting the composition of secretions in the lung, gastrointestinal tract, pancreas, 
liver and other secretory glands. In the airways, CFTR mutations result in a dehydrated viscous 
mucus that compromises mucociliary clearance and predisposes CF patients to chronic bacterial 
infections and airway inflammation [2,3]. Life expectancy in CF has improved dramatically in the last 
few decades, with the median predicted survival age of people born between 2012 and 2016 now 43 
years [4]; however, pulmonary infections remain the major cause of morbidity and mortality in 
people with CF [5]. 
The CF respiratory tract is a highly diverse and complex ecosystem with a high heterogeneity 
due to the various environmental conditions [6]. As suggested by Conrad and colleagues [7], 
resources are limited in the CF lung, and ecologically diverse populations can evolve. Typically, after 
a period of intermittent colonization of the lung, bacterial infections in CF rapidly become chronic 
with bacteria persisting until the end of the disease. It is thought that bacterial strain(s) adapt to the 
CF niche by changing their phenotype(s) and genotype(s) [8,9]; in particular, the persisting pathogens 
can adapt to disease−specific environmental factors such as anaerobic mucus layers [2], the pressure 
of the innate immune defence system of the immunocompetent host [3], and aggressive antibiotic 
therapies administered during the chronic phase of the infection [10]. In accordance with this 
hypothesis, when newly acquired bacterial strains from the environment are re-isolated after a period 
of infection in CF lungs, their virulence and pathogenicity differ, as demonstrated for Pseudomonas 
aeruginosa [11]. The adaptation process aims to increase the fitness/survival of bacteria in CF lungs 
and is generated by the activation of a specific genetic program that can guarantee bacterial genetic 
variability in stressful conditions [12]. This process ultimately results in therapy resistance, a trait that 
contributes to the progression of the lung disease, the major cause of morbidity and mortality in CF. 
To date, bacterial adaptation in CF has been widely described for P. aeruginosa; this bacterium appears 
to undergo a characteristic adaptation process resulting in the production of genetically and 
phenotypically diverse strains [13]. In this context, there is alarming evidence of an increase in 
transmissible epidemic strains in major European centers with transmission observed between 
unrelated CF patients [14,15]. Transmission between patients has been widely documented for B. 
cenocepacia [16], however, our knowledge on the generation of transmissible strains is still lacking. 
Among the Burkholderia cepacia complex (Bcc) species, B. cenocepacia is especially problematic in CF 
patients [16–18]. Colonization of the lungs of CF patients by these bacteria is associated with a 
decrease in long-term survival and, occasionally in a minority of patients, the development of the so-
called “cepacia syndrome”, that leads to a frequently fatal acute clinical decline [17]. Several studies 
have revealed that B. cenocepacia is widespread in natural habitats such as the rhizosphere of several 
crop plants, where it represents one of the predominant Bcc species [19–21]. Additionally, it has been 
reported that B. cenocepacia from natural environments are indistinguishable from clinical isolates 
[22,23] suggesting that humans may acquire Bcc directly from natural environments [21,24]. In 
support of this hypothesis, candidate determinants related to virulence and transmissibility are not 
confined solely to clinical B. cenocepacia isolates but are also spread among environmental B. 
cenocepacia isolates [25–27]. However, understanding of the adaptation process of environmental B. 
cenocepacia strains to the CF airways is still poor [28]; and whether and how B. cenocepacia 
environmental strains adapt to the airways of CF airways remains to be clarified. No data are 
available on the ability of environmental B. cenocepacia strains to adapt to the CF host. Several years 
ago, Chung and colleagues [29] showed that B. cenocepacia strains convert from a nonpersistent to a 
persistent phenotype in a mouse model of pulmonary infection. In previous work, we explored the 
virulence and pathogenic potential of environmental B. cenocepacia strains and demonstrated that 
they do not differ from clinical strains in some pathogenic traits showing a similar capacity to 
maintain a chronic respiratory infection due to the production of similar virulent factors [26]. 
Furthermore, although environmental strains appear to be less invasive than the clinical ones in 
polarized CF epithelial cells, they similarly affect epithelia integrity by modulating the presence and 
distribution of the tight junction protein ZO-1 [27]. 
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In this work, we investigated the host’s role on B. cenocepacia adaptation and pathogenicity. We 
focused our attention on the environmental strain Mex1, belonging to B. cenocepacia IIIA. It was 
collected from the rhizosphere of maize cultivated in a field in Mexico and had previously been 
characterized for its pathogenicity in vitro and in vivo [26,27]. Notably, in a mouse model of chronic 
infection, the Mex1 strain caused an extensive inflammatory cell infiltrate in the lung tissues, and has 
shown a similar capacity to maintain a chronic respiratory infection as the clinical strain LMG16656T, 
probably due to production of similar virulent factors in strains of different origin [26]. In view of the 
fact that B. cenocepacia IIIA, among the Bcc species as well as the other recA lineages of B. cenocepacia 
species, is particularly problematic for CF patients, we set up a mouse model of chronic infection to 
investigate the microbe–host interaction of the environmental strain IIIA. Thus, we carried out serial 
passages of the environmental B. cenocepacia Mex1 in mice, with each round of infection lasting 28 
days. Next, we evaluated the ability of the rescued bacteria to adapt to the murine lung tissues and 
to establish new chronic lung infections. Phenotypic analysis, genetic profiling and virulence of the 
Mex1-derived clones were also investigated. 
2. Results 
2.1. Characteristics of B. cenocepacia Mex1 Strain 
The environmental strain Mex1, belonging to B. cenocepacia IIIA, was collected from the 
rhizosphere of maize cultivated in a field in Mexico [26]. Its main characteristics are reported in Table 
1. The environmental strain has already shown pathogenic potential in both in vitro and in vivo 
models [26], a dramatic effect on tight junction integrity and on the presence and distribution of the 
tight junction protein ZO-1 in CF epithelial monolayers [27]. B. cenocepacia Mex 1 strain is also able to 
form biofilms in nutrient-rich media and can adhere to an abiotic surface as the clinical LMG16656T 
strain [30,31]. 
Table 1. Characteristics of B. cenocepacia Mex1 strain. 
Isolate  
Name 
Origin 
Sequence  
Type (ST) 
Cci-Encoded 
Genes 
CF and Non-CF 
Epithelial Cells 
Transepithelial  
Resistance (TER) 
References 
Mex1 
maize rhizosphere  
(Mexico) 
423 positive 
low-level  
invasion 
strong disruption of  
tight junction integrity 
[26,27] 
2.2. Serial Passages of the Environmental B. cenocepacia Mex1 in Mice 
We established sequential chronic infection in C57Bl/6 mice with B. cenocepacia Mex1 strain 
embedded in agar beads. The schedule of experiments is reported in Figure 1. As previously reported, 
the agar beads mimic the microaerobic/anaerobic environment that allows bacteria to grow in the 
form of microcolonies and in the mucus of CF patients [2,32]. Sequential infections were established 
in two groups of C57Bl/6NCrlBR mice challenged with 1.5 × 107 colony-forming units (CFU)/lung and 
the infection was followed for almost one month (P1) (Figure 1). 
At 28 days from the first challenge (P1), the incidence of chronic B. cenocepacia colonization was 
30% in the first group of mice and 41.67% in the second group, with no significant difference between 
the two groups of mice, confirming previous findings [26,30] (Figure 2A). No mortality was observed 
and the median value of CFU recovered after 28 days was 7.12 × 105 and 1.06 × 105, in the first and 
second group of mice, respectively (Figure 2B). For the second passage (P2), 192 single colonies 
recovered from two infected mice (96 colonies for each mice) were re-grown in vitro separately in a 
96-well plate. All 96 colonies were pulled for two different agar bead preparations and injected in 
two groups of mice, respectively. The same procedure for colony isolation and agar beads 
preparation was followed for the third and the fourth passages of chronic infection (P3 and P4) 
(Figure 1). 
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Figure 1. Schedule of sequential chronic B. cenocepacia lung infection in mice. Two groups of 
C57Bl/6NCrlBR mice (n = 8–12) were inoculated with 1.5 × 107 CFU/lung of B. cenocepacia Mex1 strain 
embedded in agar beads for 28 days (P1). After 28 days, single colonies were recovered from two 
groups of infected mice and were re-grown separately; then, they were pulled for two different agar 
bead preparations and injected in two groups of mice (n = 8–9) (P2). The third and the fourth passages 
in mice (n = 8–9) (P3 and P4) were carried out as P2 for 28 days each. 
At the second serial passage in mice (P2), the percentage of infected mice increased significantly 
to 89% in one group and 75% in the second group (Fisher exact test: p = 0.0083 P1 vs. P2). Then, the 
third and fourth passages (P3 and P4) carried out as described above led to an increase in the 
percentage of infected mice of between 89% and 100%, respectively (Chi-square Test: p = 0.0002 P1 
vs. P3; p = 0.0001 P1 vs. P3 and P4) (Figure 2A). There was no significant difference between the 
median value of CFU recovered from the first to the fourth passages in the sub-group of mice 
maintaining the infection and ranging between 1.14 × 105 and 1.32 × 106 CFU/lung (p value = 0.446 P1 
vs. P4) (Figure 2B). 
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Figure 2. Virulence of B. cenocepacia Mex1 after sequential passages in mice. C57Bl/6 mice were 
infected for four sequential passages by bacteria collected from each passage of 28 days. At each 
passage mice were sacrificed and evaluated for CFU and percentage of infected mice. (A) The 
percentage of chronically infected mice at different passages. (B) The number of CFU of B. cenocepacia 
per lung at different passages. Dots represent individual mice measurements and horizontal lines 
represent the median values. Two groups of 8–12 mice were analyzed for each passage. Statistical 
significance is indicated: ** p < 0.01, **** p < 0.0001. 
2.3. Phenotypic and Molecular Characterization of Mex1 Adapted to Murine Lungs 
Phenotypic and molecular characterization of bacterial isolates recovered after the fourth 
passage in mice was carried out, in order to determine whether phenotypic or genetic adaptation 
occurred. We examined the persistent variants isolated from two groups of eight and nine chronically 
infected mice after the fourth sequential passages when the percentage of infected mice increased to 
100%. Growth on Burkholderia cepacia selective agar (BCSA) and genetic profiling by random 
amplified polymorphic DNA (RAPD) analysis confirmed that the bacteria recovered were genetically 
indistinguishable from the initially challenged Mex1 strain (Figure 3). 
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Figure 3. Random amplified polymorphic DNA (RAPD) fingerprints of the B. cenocepacia Mex1 
challenge and some of its persisting colonies isolated from infected mice. (A) The polymorphisms 
were generated using RAPD primer 270. From left to right: L123, 123-bp molecular size marker ladder; 
Mex1 strain; clone 410801; clone 410807; clone 410808; negative control. (B) The dendrogram showing 
the clonal relatedness of some persisting colonies, performed with the Unweighted Pair Group 
Method with Arithmetic mean (UPGMA) by using mathematic averages algorithm programs integral 
to the Phoretix 1D Pro software. Lanes 2–5: Mex1 strain; clone 410801; clone 410807; clone 41080. 
B. cenocepacia Mex1 strain and its derivatives were finally tested by PCR for the presence of the 
cable pilin subunit gene (cblA), encoding the cable pilus. Both the parent and the Mex1 derivative 
strains were negative for cblA gene, while only the clinical B. cenocepacia strain LMG 16656 was found 
positive (data not shown). No differences in biofilm formation (Figure 4) or colonial morphology 
(Figure 5) between the parental Mex1 and Mex1-derived clones were observed. Indeed, the mucoid 
colonial morphology, as assessed on yeast extract mannitol (YEM) agar plates, that correlates with 
higher levels of EPS production, appeared to be a distinct feature of the Mex1 strains as well as their 
derivative clones. 
 
Figure 4. Biofilm formation of Mex1 and some of its derivatives in microtiter plate assay. No 
significant difference among Mex1 and its derivative clones was found (p > 0.05, One-way ANOVA). 
The clinical LMG16656T formed a higher biofilm in comparison with Mex1 (p = 0.0311, Student’s t-
test). The amount of biofilm was quantified by Crystal Violet staining. Absorbance was measured at 
595 nm. 
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Figure 5. Colonial morphology of Mex1, its derivative (41818 clone as an example) and the clinical B. 
cenocepacia LMG16656T on YEM agar. Strains were grown at 37 °C for 48 h. 
2.4. Survival and Relative Bacterial Loads of Mex1 and Its Derivative Clones in Infected G. mellonella Larvae 
The G. mellonella model is a valuable experimental system for determining the virulence 
properties of B. cepacia complex genetic mutants [33]. Thus, Mex1 and its derivatives recovered after 
the fourth passage in mice were screened for their ability to kill G. mellonella wax moth larvae. The 
resulting data were analyzed by determining the percentage survival of the infected larvae (Figure 
6) and by the Kaplan–Maier method (Figure 7). As expected, the environmental Mex1 strain was 
significantly less virulent than LMG16656 as assessed by the log-rank test (p = 0.0106), demonstrating 
that the G. mellonella assays were suitable to identify differences in the virulence of B. cenocepacia 
strains. Overall, most of the Mex1-derived clones were not significantly different from the parental 
Mex1 strain, with two exceptions—strains 41803 and 41818—that appeared to be more virulent than 
Mex1 (Figure 6B). 
 
Figure 6. Percent survival of G. mellonella following inoculation with Mex1, Mex1-mouse persistent 
derivatives and the clinical LMG16656T. The B. cenocepacia strains are indicated on the right: Mex1, 
thick dashed line; LMG16656, thick dotted line. Y-axis, percent survival of larvae infected with the 
indicated bacterial strains; X-axis, time post infection (days). Mex1-mouse persistent derivatives were 
recovered from two groups of eight and 9 C57Bl/6 male mice, and coded as 40 (A) and 41 (B), 
respectively. 
Int. J. Mol. Sci. 2017, 18, 2417  8 of 15 
 
 
Figure 7. Kaplan-Meier survival plots of larvae injected with the indicated strains. (A) The killing 
ability of Mex1 compared with that of 41803 and 41818 Mex1-derived clones. (B) The killing ability of 
LMG16656 compared with that of 41803 and 41818 Mex1-derived clones. Y-axis, percent survival of 
larvae; X-axis, time (days) post infection. Statistical analysis was performed by log-rank test. 
Accordingly, the Kaplan–Meier survival and the log-rank test showed a significantly higher 
virulence of these two strains respect to Mex1, with p = 0.0156 and p = 0.0087 for 41803 and 41818, 
respectively, while comparison with LMG16656 revealed no significant differences (p > 0.05) (Figure 
7). Subsequently, the 50% lethal dose (LD50) causing 50% death of infected larvae was determined. 
Results indicated that the two reference strains, Mex1 and LMG16656, showed LD50 values equal to 
250 and 166, respectively. The Mex1-derivatives were more variable with LD50 ranging from 25 
(41821) to 500 (41819). The clones 41803 and 41818 were characterized by low LD50 values, 59 and 38 
respectively. 
Overall, we have demonstrated that the Mex1 derivative clones showed a different degree of 
virulence in comparison with the parental strain. In particular, strains 41803 and 41818 were both 
significantly more virulent than the parental Mex1 strains, with a virulence degree comparable to 
that of the clinical LMG16656T strain. 
3. Discussion 
B. cenocepacia strains occur naturally in a wide range of environments and are able to persist in 
human hosts, suggesting that the virulence factors needed to colonize animals and other habitats are 
similar [34]. Among the natural environments, the rhizosphere is a huge reservoir for bacterial species 
and a source of human pathogens, due to the enhanced biomass and microbial activity as a result of 
exudation compounds from the roots [35]. In particular, the maize rhizosphere has a strong influence 
on the specific host—B. cenocepacia interactions, and represents a privileged environment of BCC 
strains [36,37]. It can also be considered as a reservoir for opportunistic human pathogenic bacteria 
[24]. Interactions with plant roots might pave the way for bacterial adaptation to mammalian and 
human cells [35]. In this study, we aimed to investigate whether the rhizosphere B. cenocepacia Mex1 
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strain, that showed a low level of virulence in vivo [26], can increase its fitness in mice establishing 
niche adaptation through serial passages in a murine model. 
Among the genetic lineages of B. cenocepacia species, recA lineage IIIA appears to have global 
distribution, predominantly among patients with CF, with high transmissibility and a high mortality 
rate [23,38,39]. Mex1 constitutes a rare environmental B. cenocepacia IIIA strain, isolated from the 
maize rhizosphere in Mexico [26,27]. Mex1 has a unique sequence type (ST), the ST 423, but 
genetically it is closely related to internationally spread clones as it belongs to the clonal complex 31, 
the largest clonal complex of all STs reported in the Multi-Locus Sequence Typing (MLST) B. cepacia 
complex database [16]. Until now, the adaptation process of B. cenocepacia to the host environment 
has been investigated for clinical isolates only [40] and, despite the description of several virulent 
factors, understanding is still poor [41]. Considering environmental B. cenocepacia strains, increased 
fitness of the B. cenocepacia HI2424 strain, belonging to the recA lineage IIIB, has been shown 
suggesting the adaptation of a soil isolate to the onion model [42]. In this case, B. cenocepacia 
adaptation was associated with reduced virulence and a loss of pathogenicity to the nematode C. 
elegans. The large, multireplicon genome and the presence of insertion sequences confer genome 
plasticity that could explain the versatility of B. cenocepacia bacteria and their ability to rapidly adapt 
to new niches [28]. Environmental strains have defense mechanisms that confer to them a survival 
advantage in this niche and they have been shown to infect various hosts, including mammals, 
nematodes and plants [43]. 
This study revealed that the rhizosphere B. cenocepacia Mex1 strain, with a low virulence in mice, 
increased its ability to cause a chronic lung infection following serial passages in mice that adapt to 
“local environmental” conditions in the murine lung tissues and establish chronic infections in almost 
all the infected mice. Our results suggest that chemical–physical characteristics of the host play a role 
in the selection of virulent bacteria. The phenotypic and genotypic tests we performed did not reveal 
any differences between strains. Colonial morphology revealed that the phenotype of the Mex1-
derived clones recovered from infected mice were indistinguishable from the challenge strain. Our 
findings suggest that the Mex1 strain and its derivative clones were mucoid, in agreement with 
results obtained by Zlosnik and colleagues [44], who suggested that the capacity to elaborate EPS 
may be critical for survival in the environment, the natural niche of B. cepacia complex bacteria. Serial 
passages in mice did not determine any phenotypic switching from to nonmucoid to mucoid forms, 
as that of clinical and virulent B. cenocepacia strains. Also, no differences were observed in the genetic 
fingerprinting of the parental and the Mex1-derived clones. At any rate, RAPD analysis does not 
exclude the possibility that point mutations, such as SNPs or other point mutations, may have 
occurred [45].  
When we evaluated the virulence of Mex1-derived clones in the G. mellonella larvae infection 
model, two Mex1-derived clones with a virulence degree more similar to that of the clinical and 
epidemic LMG16656 strain were found, suggesting adaptation to mice and the acquisition or 
differential expression of virulence factors. G. mellonella is an excellent model for assessing the 
virulence for a range of microorganisms and provides a rapid and cost-effective alternative for 
screening a large number of bacteria [46]. The wax moth larvae infection model has recently gained 
popularity in Burkholderia research and has been employed to compare virulence among different 
BCC species [33]. Recently, it was used to assess the efficacy of the combination therapy (tobramycin 
with econazole or miconazole) for B. cenocepacia [47]. From our results, we can speculate that the 
ability of B. cenocepacia to survive and replicate in various growth niches is due to the high genomic 
plasticity of this bacterial species and to the expression of host specific virulence factors. When 
properly regulated, this may help it to compete for survival in different settings [41]. As also 
suggested by Koskiniemi and colleagues [48], following growth inside a host selection can benefit 
bacterial mutants through an altered expression of virulence genes that better suit the environment 
of the host. 
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4. Materials and Methods 
4.1. Bacteria and Culture Conditions 
The bacterial strain used in this study and its properties are shown in Table 1. 
4.2. Ethical Statement 
Animal studies adhered strictly to the Italian Ministry of Health guidelines for the use and care 
of experimental animals. This study was conducted according to protocols approved by the 
Institutional Animal Care and Use Committee (IACUC, protocol #369 of 28 July 2008) of the San 
Raffaele Scientific Institute (Milan, Italy). 
4.3. Sequential Infection in Mice 
Mex1 was included in the agar beads prepared according to the previously described method 
[26]. Briefly, bacteria were cultured overnight in nutrient broth (NB) at 37 °C to the stationary phase. 
For agar beads preparation in P2–P4, bacteria isolated from plates were grown in NB broth in a 96-
well plate at 37 °C overnight, pooled and centrifuged at 4000 rpm for 10 min. The cells were harvested 
by centrifugation and re-suspended in 1 mL of PBS (PH 7.4). Bacteria were added to 9 mL of 1.5% 
NA and subsequently pipetted forcefully into 150 mL of heavy mineral oil, which was kept at 50 °C 
for bead preparation. The size of the beads was verified microscopically and only those preparations 
containing beads of 100 µm to 200 µm in diameter were used. The number of B. cenocepacia CFU in 
the beads was determined by plating serial dilutions of the homogenized bacteria-bead suspension 
on NA plates. The two groups of 8 and 12 C57Bl/6 male mice (Charles River), 6–8 weeks old (20–22 
g) were injected with 1.5–2.0 × 107 CFU/lung and the infection was followed for 28 days. Before 
infection, mice were anesthetized as previously described [30]. After infection, mice were monitored 
daily for the following clinical signs: coat quality, posture, ambulation, hydration status, and body 
weight. After 4 weeks, mice were sacrificed, and the lungs were homogenized. Serially diluted lung 
homogenate samples were plated on NA and the viable cell counts of B. cenocepacia were evaluated. 
Bacterial strains were recovered and the percentage of infected mice was evaluated. Recovery of 
>1000 CFU from lung cultures was indicative of chronic infection. Next, for the second passage, 192 
single colonies recovered after 28 days, from two groups of infected mice were re-grown separately 
in 96 well plates. Then, they were pooled for two different agar bead preparations and injected in two 
groups of mice (n = 8–9, respectively). Thereafter, third and fourth passages in mice were carried out 
as described above. 
4.4. Molecular Characterization of Mex1-Derived Clones 
4.4.1. Random Amplified Polymorphic DNA (RAPD) Fingerprinting 
The environmental B. cenocepacia Mex1 strain and its persisting derivatives recovered from 
infected mice were genetically typed by random amplified polymorphic DNA (RAPD) analysis, as 
previously described [49]. Each strain was tested in triplicate, and the entire experiment was repeated 
three times to verify the RAPD reproducibility. The generated fingerprints were analyzed using the 
Quantity One software package (Bio-Rad Laboratories, Milan, Italy) and Phoretix 1D PRO software 
(Phoretix International, Newcastle upon Tyne, UK). The Dice coefficient index was used as similarity 
measure. The dendrogram was created within Phoretix 1D Pro software by using the unweighted 
pair group method with arithmetic averages (UPGMA) method. 
4.4.2. PCR Amplification of cblA Gene 
The 664-bp cblA DNA coding for the cable pilus was amplified with the primers CBL1 and CBL2, 
according to the procedure described by Clode and colleagues [50]. 
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4.5. Biofilm Formation 
Biofilm formation was assessed using the 96-well plate assay and staining the sessile and 
adherent cells with crystal violet (CV) as described previously [51], with minor modifications [28]. B. 
cenocepacia strains (Mex 1, Mex1-derived clones and the clinical LMG16656T) were inoculated from 
pure cultures grown in M9 minimal medium to mid-exponential (OD600 ~ 0.5) phase into at least 6 
wells of flat-bottomed 96-well polyvinyl chloride microtiter plates (Greiner Bio-one, Frickenhausen, 
Germany). Biofilm biomass was quantified by crystal violet staining. Absorbance was measured at 
595 nm using a Victor3 multilabel counter (Perkin-Elmer, Milan, Italy). Each strain was tested in 
triplicate, and the entire experiment was repeated three times. 
4.6. Growth on YEM Yeast Extract-Mannitol (YEM) Agar 
Overnight cultures of bacteria were harvested, standardized to an OD590 of 1.0 in PBS, and 
adjusted to approximately 5 × 106 CFU·mL−1. This bacterial suspension was used to inoculate (via a 
sterile pipette tip) yeast extract medium (YEM; 0.5 g of yeast extract L−1 and 4 g of mannitol L−1 
supplemented with 15 g of agar L−1) agar plates. Plates were incubated at 37 °C for 48 h prior to 
measuring the capacities of isolates to elaborate EPS. 
4.7. Screening of Mex1-Derived Clones in the G. mellonella Model 
The G. mellonella infection assay was carried out as described by Uehlinger and colleagues [52] 
with minor modifications. Overnight bacterial cultures were grown in Luria–Bertani (LB) broth, 
diluted 1:100 in the same medium and grown to an optical density at 600 nm (OD600) of 0.4. Cultures 
were pelleted, resuspended in 10 mM MgSO4 plus 1.2 mg/mL ampicillin and adjusted to OD600 = 1. A 
5-µL aliquot (approximately 1 × 106 CFU/mL) was injected into the hindmost left proleg. For 50% 
lethal dose (LD50) experiments, a series of 10-fold serial dilutions containing from 106 to 0 bacteria 
were injected into G. mellonella larvae. Ten to fifteen healthy larvae were injected for each strain and 
incubated in Petri dishes at 30 °C in the dark. The number of live and dead larvae was scored 24, 48 
and 72 h after infection; dead larvae were those that did not move in response to touch. All the tests 
were performed in triplicate. Control larvae were injected with 5 µL of buffer only. 
4.8. Statistical Analysis 
In vivo data were statistically analyzed by using GraphPad Prism. Data analysis was performed 
using a non-parametric two-tailed Mann–Whitney U-test for single comparison for CFU counts. 
Incidences of chronic colonization were compared using Fisher exact test. Differences were 
considered statistically significant at p values < 0.05. 
Biofilm data were analyzed using One-way ANOVA (Prism GraphPad version 6.0 Software Inc., 
San Diego, CA, USA), considering p < 0.05 as the limit of statistical significance. 
The Kaplan-Meier curves were used to compare the survival of groups of larvae injected with 
the B. cenocepacia strains. Differences in survival were calculated by using the log-rank test. LD50 
(CFU) value of each strain was calculated by fitting a linear regression. Survival and LD50 were 
performed using Prism GraphPad version 6.0. A p-value of <0.05 was considered to be statistically 
significant. 
5. Conclusions 
The present study evaluated the ability of the environmental B. cenocepacia Mex1 strain, isolated 
from maize-rhizosphere, to persist and increase its virulence by serial passages during long-term 
chronic airways infection in mice. In conclusion, we found that the environmental B. cenocepacia strain 
increased its capacity to cause a chronic lung infection after serial passages in mice, adapting to the 
local environmental conditions of murine lung tissues and establishing chronic infection. However, 
how environmental bacteria adapt in the complex and variable environment of the host is still largely 
unknown. Clonal variants with increased virulence in non-vertebrate hosts were found. However, 
in-depth characterization of Mex1 derivative clones by whole-genome sequencing and comparative 
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bioinformatics analysis is necessary to understand whether intraclonal diversification occurred; this 
could lead to new targets for future anti-B. cenocepacia treatment strategies. Understanding the 
mechanisms of niche specialization of environmental strains and identifying the common targets of 
adaptation to the lung environment will allow us to evaluate the potential risk of infection with 
opportunistic pathogens. 
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